KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Return on Equity: 2011-2025

Historic Return on Equity for Rigel Pharmaceuticals (RIGL) over the last 13 years, with Sep 2025 value amounting to 1.14%.

  • Rigel Pharmaceuticals' Return on Equity rose 131.00% to 1.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.14%, marking a year-over-year increase of 131.00%. This contributed to the annual value of -1.38% for FY2024, which is 257.00% down from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Return on Equity stood at 1.14%, which was down 41.66% from 1.95% recorded in Q2 2025.
  • Rigel Pharmaceuticals' Return on Equity's 5-year high stood at 7.02% during Q3 2022, with a 5-year trough of -54.15% in Q2 2022.
  • Moreover, its 3-year median value for Return on Equity was 0.83% (2023), whereas its average is 0.89%.
  • In the last 5 years, Rigel Pharmaceuticals' Return on Equity plummeted by 5,404bps in 2022 and then soared by 5,559bps in 2023.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Return on Equity stood at -0.45% in 2021, then surged by 395bps to 3.50% in 2022, then tumbled by 267bps to 0.83% in 2023, then plummeted by 391bps to -3.08% in 2024, then surged by 131bps to 1.14% in 2025.
  • Its Return on Equity stands at 1.14% for Q3 2025, versus 1.95% for Q2 2025 and 3.40% for Q1 2025.